

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

SECTION 1. IDENTIFICATION

Product name : Ganirelix Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Reproductive toxicity : Category 1B

Specific target organ
systemic toxicity - repeated
exposure : Category 1 (Bone marrow, Liver, Adrenal gland, spleen, ovaries)

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, ovaries) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Ganirelix	124904-93-4	≥ 0.01 - < 0.1

SECTION 4. FIRST AID MEASURES

- | | |
|---|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : May damage fertility. Suspected of damaging the unborn child.
Causes damage to organs through prolonged or repeated exposure. |

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe vapors or spray mist.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice.
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ganirelix	124904-93-4	TWA	0.2 µg/m3 (OEB 5)	Merck
		Wipe limit	2 µg/100 cm ²	Merck

- Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

- Respiratory protection : No personal respiratory protective equipment normally required.
- Hand protection
Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : Aqueous solution
- Color : No data available
- Odor : No information available.
- Odor Threshold : No data available
- pH : 5

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	23 hPa (20 °C)
Relative vapor density	:	No data available
Relative density	:	1
Solubility(ies)	:	
Water solubility	:	completely miscible
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:**Ganirelix:**

Acute toxicity (other routes of administration) : LD50 (Rat): 40 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Ganirelix:**

Species: Rabbit
Result: Mild eye irritation
Method: Draize Test

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Ganirelix:**

Test Type: Maximization Test
Species: Guinea pig
Result: negative

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**Ganirelix:**

- | | | |
|-------------------------------------|---|--|
| Genotoxicity in vitro | : | Test Type: reverse mutation assay
Species: Salmonella typhimurium
Result: negative |
| | : | Test Type: reverse mutation assay
Species: Escherichia coli
Result: negative |
| | : | Test Type: in vitro test
Species: Chinese hamster ovary cells
Result: negative |
| Genotoxicity in vivo | : | Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative |
| Germ cell mutagenicity - Assessment | : | Weight of evidence does not support classification as a germ cell mutagen. |

Carcinogenicity

Not classified based on available information.

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Ingredients:**Ganirelix:**

- | | | |
|----------------------|---|---|
| Effects on fertility | : | Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Subcutaneous
Duration of Single Treatment: 13 Weeks
Fertility: LOAEL: 0.1 µg/kg
Result: Effects on fertility. |
| | | Test Type: Fertility/early embryonic development
Species: Rat, female |

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

Application Route: Subcutaneous
Duration of Single Treatment: 8 Weeks
Fertility: LOAEL: 10 µg/kg
Result: No effects on mating performance., Effects on fertility.

Test Type: Fertility
Species: Monkey
Application Route: Subcutaneous
Fertility: NOAEL: 0.02 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat, female
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 10 µg/kg
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rabbit, female
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 30 µg/kg
Result: Embryo-fetal toxicity.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, ovaries) through prolonged or repeated exposure.

Ingredients:**Ganirelix:**

Routes of exposure: Ingestion
Target Organs: Bone marrow, Liver, Adrenal gland, spleen, ovaries
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Ingredients:****Ganirelix:**

Species: Rat
NOAEL: 0.02 mg/kg
LOAEL: 2 mg/kg
Application Route: Subcutaneous
Exposure time: 6 Months
Target Organs: Bone marrow

Species: Mouse, female

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

LOAEL: 0.3 mg/kg
Application Route: Subcutaneous
Exposure time: 3 Months
Target Organs: Liver, Adrenal gland, spleen, Ovary

Species: Mouse, male
LOAEL: 3 mg/kg
Application Route: Subcutaneous
Exposure time: 3 Months
Target Organs: Liver, Adrenal gland, spleen

Species: Monkey
NOAEL: 2.5 mg/kg
Application Route: Subcutaneous
Exposure time: 6 Months
Remarks: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Ingredients:****Ganirelix:**

Inhalation : Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****Ganirelix:****Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Chronic Health Hazard

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Water

7732-18-5

Ganirelix Formulation


Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION**Further information****NFPA:****HMIS® IV:**

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/11/2016
5.2	06/20/2017	22224-00010	Date of first issue: 10/15/2014

erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/20/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8